Drugs / Salmeterol/fluticasone
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02603393 Comparator | Nov 2015 → Jul 2017 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Salmeterol/fluticasone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02603393 ↗ |
| Known as | salmeterol/fluticasone propionate | “Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™” NCT02603393 ↗ |
| Route | Inhaled | “Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™” NCT02603393 ↗ |